Numeta G19iJu
L-Alanine 0.466g · L-Arginine 0.489g +26 more
Injections · Prescription medication · Combination
Baxter Korea Co., Ltd.
MFDS item code 201805068 · Approved 2018.12.13
Correction of nutritional deficiencies through pediatric parenteral nutrition (fluids, electrolytes, amino acids, etc.)
This medication is used for children over two years of age who are unable to receive adequate nutrition orally or via enteral nutrition, supplying fluids, electrolytes, amino acids, and calories to improve their nutritional status.
The dose is determined based on the patient's condition, caloric expenditure, body weight, age, metabolic capacity, and any additional calories or protein supplied orally or through the gastrointestinal tract. The maximum recommended dose should not be exceeded. Because the composition of the three-chamber bag is fixed, it may not meet all of the patient's nutritional requirements simultaneously. There may be clinical situations in which the patient requires nutrients in proportions different from the fixed composition. The maximum recommended infusion rate per hour and the daily dose are determined according to the individual components. If any one component is administered at its maximum dose, the maximum daily dose of this drug has been reached. The maximum recommended infusion rate per hour and daily dose are as follows. Three-chamber bag (1000 mL) Maximum infusion rate (mL/kg/hour) 4.6 Equivalent to: Amino acids (g/kg/hour) 0.11 Glucose (g/kg/hour) 0.89 Lipids (g/kg/hour) 0.13 Maximum infusion volume (mL/kg/day) 83.6 Equivalent to: Amino acids (g/kg/day) 1.9 Glucose (g/kg/day) 16.0 Lipids (g/kg/day) 2.3 Osmolarity (approximately mOsm/L) 1460 Because this undiluted drug has high osmolarity, it can be administered only through a central vein. However, when sufficiently diluted with Water for Injection, its osmolarity decreases, allowing infusion into a peripheral vein. Gradually increase the infusion rate during the first hour of administration. When discontinuing this drug, gradually decrease the infusion rate during the hour before stopping administration. Adjust the infusion rate based on the dose to be administered, daily intake, and infusion duration. Do not infuse the same bag for more than 24 hours. Cyclic infusions should be managed according to the patient's metabolic tolerance. Parenteral nutrition therapy may be continued for as long as the patient's clinical condition requires. This drug contains electrolytes. Electrolyte preparations may be supplemented as needed based on the physician's judgment and the patient's clinical needs, and vitamins and trace elements may be added. (See Precautions for Use, section 10, Precautions for Administration.)
This medication should be used cautiously in premature infants and low-birth-weight infants, as it may increase plasma free fatty acid levels, leading to fat accumulation in pulmonary vessels and reported mortality, especially in premature infants with severe respiratory diseases. It should not be administered to patients with allergies to eggs, soybeans, peanuts, or hypersensitivity to any components of this medication. Furthermore, it is contraindicated in patients with congenital amino acid metabolism disorders, those with abnormally high blood levels of sodium, potassium, magnesium, calcium, or phosphorus, severe hyperglycemia, hyperlipidemia, or severe lipid metabolism disorders. In patients with pulmonary edema, heart failure, renal failure, severe hepatic failure, endocrine and metabolic disorders, and severe blood coagulation disorders, close monitoring of fluid balance, electrolyte status, liver function, blood cell counts, etc., is necessary during administration. Care is particularly important if the nutritional supply does not match the patient's needs or if metabolic capacity is uncertain, as metabolic disorders may occur. In clinical trials, adverse reactions such as hypophosphatemia, hyperglycemia, hypercalcemia, hypertriglyceridemia, biliary disorders, and so on have been commonly reported, along with the possibility of skin necrosis or soft tissue damage. Serious side effects such as fat overload syndrome or breathing difficulties due to pulmonary vascular deposits can occur from improper administration. If allergic reactions occur, administration must be stopped immediately, and this medication contains corn-derived glucose, requiring caution in patients allergic to corn. Additionally, this medication should not be administered concurrently with calcium-containing intravenous solutions, as precipitates may form. When using intravenous catheters, there is a risk of infection and sepsis; thus, aseptic techniques and careful catheter management are essential. The possibility of fat overload syndrome and refeeding syndrome must also be considered when adjusting the nutritional supply carefully. This medication must be properly diluted and administered through central veins; peripheral venous administration carries a risk of tissue damage due to extravasation. Blood glucose, electrolytes, liver and kidney function, blood cell counts, and coagulation status should be periodically monitored during administration, and any signs of abnormalities should be addressed immediately. There is insufficient safety data for pregnant and breastfeeding women, so risks and benefits should be carefully evaluated before administration. In the case of overdose, symptoms like vomiting, tremors, electrolyte imbalances, fluid overload, and acidosis may appear, necessitating immediate cessation of administration and proper emergency care. No specific antidote exists, and in severe cases, treatment such as hemodialysis may be required. This medication is for single use only; any unused portion remaining after opening should not be stored. To prevent air embolism during the administration process, bags should not be connected continuously, and the mixed solution should be stored shielded from light.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to avoid contact with air, and should be kept in a cool place between 1 and 25 degrees Celsius. It is also important to avoid freezing. Proper storage will help maintain the efficacy of the medication.
The amino acid and sugar solutions are transparent liquids that are colorless to slightly yellow, while the fat solution is a homogeneous cloudy liquid, separated into three spaces by two membranes within a single transparent parenteral plastic bag.
1000 ml (Amino Acid Solution 392ml, Sugar Solution 383ml, Fat Solution 225ml) / Bag
Even with the same ingredient, strength, dosage form and how it is taken can differ.
L-Alanine 0.466g · L-Arginine 0.489g +26 more
Injections · Prescription medication · Combination
Baxter Korea Co., Ltd.
L-Alanine 0.466g · L-Arginine 0.489g +26 more
Injections · Prescription medication · Combination
Baxter Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.